+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

BioPorto AS (BIOPOR) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 53 Pages
  • October 2024
  • GlobalData
  • ID: 4829650
BioPorto AS (BIOPOR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

BioPorto AS (BioPorto) is an in-vitro diagnostics company that offers a wide range of specialized monoclonal antibodies, antibody-based diagnostic assays, and biomarkers for the identification and management of seriously ill patients. It employs these monoclonal antibodies in its own biomarker programs. The company’s comprehensive antibodies’ portfolio serves the R&D requirements of diagnostic and pharmaceutical companies. BioPorto evaluates its biomarker candidates derived from its antibody portfolio for early detection of acute kidney injury and mannan-binding lectin (MBL) for immune response, and also investigates potential candidates in antibiotics, and immune defense. The company distributes its products worldwide through its own sales team, distributors, and through partnership with original equipment manufacturers (OEMs). It has subsidiaries in Denmark and the US. BioPorto is headquartered in Copenhagen, Denmark.

BioPorto AS Key Recent Developments

  • Oct 21, 2024: BioPorto Announces Changes to the US Commercial Organization
  • May 30, 2024: BioPorto Appoints Chief Financial Officer
  • Apr 10, 2024: BioPorto Appoints Chief Legal Officer
  • Apr 05, 2024: New Board Candidate for the upcoming Annual Geneal Meeting

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • BioPorto AS - Key Facts
  • BioPorto AS - Key Employees
  • BioPorto AS - Key Employee Biographies
  • BioPorto AS - Major Products and Services
  • BioPorto AS - History
  • BioPorto AS - Company Statement
  • BioPorto AS - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • BioPorto AS - Business Description
  • Product Category: Antibodies
  • Overview
  • Performance
  • Product Category: ELISA Kits
  • Overview
  • Performance
  • Product Category: NGAL tests
  • Overview
  • Performance
  • Product Category: Royalty and other revenue
  • Performance
  • Geographical Segment: Asia
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: North America
  • Performance
  • R&D Overview
  • BioPorto AS - Corporate Strategy
  • BioPorto AS - SWOT Analysis
  • SWOT Analysis - Overview
  • BioPorto AS - Strengths
  • BioPorto AS - Weaknesses
  • BioPorto AS - Opportunities
  • BioPorto AS - Threats
  • BioPorto AS - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • BioPorto AS, Medical Equipment, Deals By Year, 2018 to YTD 2024
  • BioPorto AS, Medical Equipment, Deals By Type, 2018 to YTD 2024
  • BioPorto AS, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Oct 21, 2024: BioPorto Announces Changes to the US Commercial Organization
  • May 30, 2024: BioPorto Appoints Chief Financial Officer
  • Apr 10, 2024: BioPorto Appoints Chief Legal Officer
  • Apr 05, 2024: New Board Candidate for the upcoming Annual Geneal Meeting
  • Apr 04, 2024: Correction: BioPorto Announces Annual Results for 2023
  • Apr 02, 2024: BioPorto Appoints Peter Mørch Eriksen as Permanent Group Chief Executive Officer
  • Apr 02, 2024: BioPorto to Host Annual Earnings Webcast
  • Oct 20, 2023: BioPorto to Host Third Quarter 2023 Earnings Webcast and Analyst Call
  • Sep 19, 2023: BioPorto Initiates Search for new CFO as Neil Goldman Resigns
  • May 10, 2023: BioPorto announces interim results for the first three months of 2023
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • BioPorto AS, Key Facts
  • BioPorto AS, Key Employees
  • BioPorto AS, Key Employee Biographies
  • BioPorto AS, Major Products and Services
  • BioPorto AS, History
  • BioPorto AS, Subsidiaries
  • BioPorto AS, Key Competitors
  • BioPorto AS, Ratios based on current share price
  • BioPorto AS, Annual Ratios
  • BioPorto AS, Interim Ratios
  • BioPorto AS, Medical Equipment, Deals By Year, 2018 to YTD 2024
  • BioPorto AS, Medical Equipment, Deals By Type, 2018 to YTD 2024
  • BioPorto AS, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • BioPorto AS, Performance Chart (2019 - 2023)
  • BioPorto AS, Ratio Charts
  • BioPorto AS, Medical Equipment, Deals By Year, 2018 to YTD 2024
  • BioPorto AS, Medical Equipment, Deals by Type, 2018 to YTD 2024

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Accelerate Diagnostics Inc
  • Novasep Holding SAS
  • MilliporeSigma
  • Quidel Corp
  • Anteotech Ltd
  • Abcam Ltd
  • bioMerieux SA
  • InVivo BioTech Services GmbH
  • DiaSorin SpA
  • Ortho Clinical Diagnostics Holdings Plc
  • OraSure Technologies Inc
  • FUJIFILM Diosynth Biotechnologies USA Inc
  • Bio-Rad Laboratories Inc